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INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity is a disabling clinical 
symptom that is prevalent among patients suffering from cerebral palsy. The treatment of spasticity with botulinum toxin type A 
(BTX-A) is a well-established option in the interdisciplinary management of spasticity, providing focal reductions in muscle tone 
in cerebral palsy patients. 
OBJECTIVE: The aim of this retrospective study was to describe the effect of multilevel BTX-A injections in the lower extremi-
ties, focusing mainly on gross motor function and functional status in cerebral palsy patients. 
METHODS: Data from 71 cerebral palsy patients (64% male, 36% female, mean age 6.7 ±3.2 years) were analyzed retrospectively. 
We used the Ashworth and Tardieu scales to evaluate the degree of spasticity. Motor function was measured by the Gross Motor 
Function Measure (GMFM–88), and functional status was classified by the Gross Motor Function Classification System (GMFCS 
I-V). Multilevel BTX-A injections were applied after sedation and with electrostimulation guidance. The evaluations were repeated 
every three months, and the patients were followed for six months. 
RESULTS: We found that the Ashworth and Tardieu scores decreased significantly at the three-month evaluation (p<0.05) but 
not at the six-month evaluation (p>0.05). Although the improvement in spasticity was not maintained at the six-month evaluation, 
GMFM-88 scores increased significantly at the three- and six-month assessments. GMFSC levels showed no change in the three- 
and six-month assessments. 
CONCLUSION: We believe that a single multilevel BTX-A injection reduces spasticity and improves motor function in children 
with cerebral palsy. 
KEYWORDS: Cerebral palsy; Botulinum toxin injection; GMFM; Spasticity; Children.
INTRODUCTION
Cerebral palsy (CP) is the most common cause of 
physical disability in children, with an incidence of 1.5-
3 cases per 1000 live births.1–3 Spasticity is a disabling 
clinical symptom that is prevalent in those with CP.2 The 
primary problems associated with spasticity are the loss of 
balance, strength and selective motor control of the muscles, 
as well as increased muscle tone, leading to secondary 
problems such as fixed contractures and bony deformities, 
causing severe motor dysfunction3–6 in patients. Treatment 
with botulinum toxin type A (BTX-A) has been a well-
established option in the interdisciplinary management of 
spasticity since the late 1980s, providing focal reductions 
in muscle tone in CP patients.2 However, interpretations of 
the literature regarding this subject are challenging because 
of the difficulties of measuring spasticity and functional 
changes in children. 
Defining the goals of CP treatment is one of the main 
issues in its management. These goals, which should be 
individualized for each patient, are to reduce muscle tone, 
increase the range of motion of the joints, improve the 614
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function of upper and lower extremities, delay the need for 
surgery, and predict surgical results.3,7 BTX-A injections 
should always be considered as an adjunctive treatment 
to traditional therapies, including physiotherapy, orthoses, 
occupational therapy, and serial casting.3,8
Several randomized and non-randomized controlled 
studies have demonstrated the effectiveness of BTX-A 
injections in reducing muscle tone, increasing the range of 
motion, and improving posture and gait in CP patients.8–11 
Nevertheless, some studies have demonstrated little benefit 
from BTX-A with respect to functional gains and quality of 
life.7 Although this discrepancy between the various studies 
may be explained by differences in method, this point 
requires further elucidation. 
 The aim of this retrospective study was to describe 
our experience regarding the effect of multilevel BTX-A 
injections in the lower extremities, mainly pertaining to 
gross motor function and functional status in CP patients. 
METHODS
Participants
Data from 131 children with CP who were treated 
with BTX-A from 2003 to 2008 were investigated for 
inclusion in this retrospective study. Records were selected 
from patients with spastic CP (hemiplegia, diplegia or 
quadriplegia), well-documented clinical histories and 
appropriate physiotherapy and orthoses for day and 
night use. Records were excluded for patients with 
these conditions: spasticity predominantly in their upper 
extremities, fixed contractures and hip, knee and ankle 
deformities; or a history of previous surgery or application 
of intrathecal baclofen. A deficit in cognitive function was 
not a criterion for exclusion. Patients who were received 
more than one injection session and those with records 
lacking sufficient data were also not included. Of the 131 
patients evaluated, the records of 71 (64% male, 36% 
female, mean age 6.7 ±3.2 years) who received one BTX-A 
injection were selected. Informed consent was obtained 
from the children’s parents before the procedure. 
Procedure
CP patients were referred to the Physical Medicine 
and Rehabilitation (PM&R) clinic after being evaluated 
by the Pediatric Neurology clinic and were examined 
and documented by a PM&R specialist. Following this 
recording procedure, pediatric neurology specialists 
and orthopedic surgeons re-evaluated the patients and 
individualized therapeutic goals were planned. The 
children’s motor functions were measured by the Gross 
Motor Function Measure (GMFM–88)13. GMFM is 
a criterion reference tool that is designed to measure 
changes in gross motor function over time in children with 
motor impairment and has been validated for sensitivity 
to changes in children with CP. Functional status was 
classified by GMFCS I-V. GMFCS for CP is based on self-
initiated movement, which represents the child’s present 
abilities and limitations in motor function.14 Spasticity was 
assessed using the Ashworth and Tardieu scales.15, 16 The 
assessments were repeated at the three- and six-month 
points following the BTX-A injection. 
Intervention 
The injections were administered using a multilevel 
approach at a single injection session. The various 
muscle groups that were injected in each session were the 
gastrocnemius, medial and lateral hamstring muscles, the 
adductors, iliopsoas, tibialis posterior, soleus and rectus 
femoris. Of the 131 children assessed, 71 had received one 
BTX-A session with sufficient follow-up data. A standard 
concentration of BTX-A (Botox 100 U/ml or Dysport 500 
U/ml) was used. The toxin dosage was calculated using a 
dose conversion ratio of 5:1 U for Dysport: Botox, which 
was shown to be similar in clinical efficacy between two 
formulations.5 The dosage for Botox (Allergan, USA) 
ranged from 15–20 U/kg, and that for Dysport (Ipsen, UK) 
was 30 U/kg. If only one side was injected, the dose was 
15 U/kg. The total maximum doses for Botox and Dysport 
were 300 U and 500 U, respectively. The total muscle 
dose was divided between 2–4 injection sites, depending 
on muscle size. The injections were administered under 
electromyography (EMG) or electrical stimulation guidance 
for the exact identification of target muscles and motor 
points. Special monopolar needle electrodes (Myoject) were 
used for the injections. Oral sedation with midazolam 0.5 
mg/kg was administered 30 minutes before administration 
of the injections.7
Physical Therapy Program
The patients underwent regular physiotherapy sessions 
before the BTX-A injections. An intensive physiotherapy 
program was started one week after the multilevel BTX-A 
injections. The first 3 weeks consisted of 45 min/day, 5 
days/week, after which the level was decreased to 3 days/
week for an additional 8 weeks. The physiotherapy sessions 
consisted of active and passive stretching of flexor muscles, 
strengthening of extensor muscles, and balance and gait 
training.615
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Orthoses
Ankle foot orthoses were used to support full knee 
extension and to correct plantar flexion deformity of the 
ankle. Night splints were prescribed to maintain the neutral 
position of the ankle and to ensure sufficient stretching of the 
plantar flexor muscles. 
Follow-up
The patients were assessed at baseline and every three 
months post-injection for six months.
RESULTS
Data from the 71 patients who were followed for 
six months were evaluated. The demographic data 
are presented in Table 1. The distribution of patients 
according to GMFCS level is shown in Figure 1. The 
improvements in Ashworth scores and Tardieu test 
findings are shown in Tables 2 and 3. Total GMFM–88 
scores are shown in Table 4. A comparison of the initial 
total GMFM-88 scores with those at the three- and six-
month evaluations is shown in Figure 2. The GMFM 
(lying and rolling) and GMFM (crawling and kneeling) 
scores improved significantly at the six-month evaluation 
compared with the initial scores (p<0.05 and p<0.01, 
respectively). The GMFM (sitting) and GMFM (standing) 
scores improved significantly at the three- and six-month 
evaluations (p<0.05 and p<0.001 (sitting); p<0.001 
(standing) for both, respectively). The improvements in 
GMFM (walking, running and jumping) scores are shown 
in Figure 3. The GMFCS scores showed no significant 
improvements at any assessment (p>0.05). 
Table 1 - Patient characteristics.
Characteristics BTX-A (n=71)
n (%)
Sex
        Male
        Female
47 (65)
24 (35)
Age (years)
        1–4
        5–8
        9–12
42 (59)
21 (30)
 8 (11)
Diagnosis
        Diplegia
        Hemiplegia
        Quadriplegia
33 (47)
12 (17)
26 (36)
Figure 1 - The distribution of patients according to the GMFCS levels. 
Table 2 - Ashworth scores. 
MUSCLES Initial
Mean ±SD
Third month
Mean ±SD
Sixth month
Mean ±SD
Hip Flexor Muscles 
                    Right
                    Left
0.98 ±1.05 ¥
1.01 ±1.09 ¥
0.65 ±0.79
0.68 ±0.80
0.87 ±0.96
0.94 ±0.99
Hip Adductor Muscles
                    Right
                    Left
1.61 ±1.47 ¥
1.74 ±1.51 ¥
1.25 ±1.25
1.32 ±1.25 †
1.47 ±1.36
1.58 ±1.39
Hamstring Muscles
                    Right
                    Left
2.10 ±1.55 *
2.18 ±1.54 ¥
1.58 ±1.33 †
1.65 ±1.33 †
2.08 ±1.48
2.10 ±1.48
Gastrosoleus Muscles
                    Right
                    Left
2.61 ±1.21 *
2.70 ±1.25 *
1.90 ±1.12 £
1.97 ±1.25 £
2.53 ±1.25
2.64 ±1.27
*Initial and third month comparisons were statistically different (p<0.001). ¥Initial and third month comparisons were statistically different (p<0.05). †Third 
and sixth month comparisons were statistically different (p<0.05).£Third and sixth month comparisons were statistically different (p<0.001).
DISCUSSION
This retrospective study evaluated the effect of multilevel 
BTX-A injections and intensive physiotherapy on motor 
function and spasticity in children with CP six months after 
injection. The results showed that multilevel injections of 
the muscles of the lower extremities significantly reduced 
muscle tone. More importantly, these injections also resulted 
in improvements in patients’ motor functions.616
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When injected into the muscle, BTX-A produces local 
muscle weakness by blocking the release of acetylcholine 
at the neuromuscular junction. The toxin’s effect on motor 
function is observed within a few days following injection 
and lasts between three and four months, a period related to 
the time required for new synaptic connections to occur with 
collateral sprouting17. Several studies have proved the long-
term safety and efficacy of this treatment. A meta-analysis 
of double-blind, randomized controlled clinical trials showed 
the superior effectiveness of BTX-A over a placebo on 
the improvement of gait in patients with spastic equinus 
foot.18 The decreased spasticity allows better stretching of 
the agonist muscles, increases the range of motion of the 
joints and strengthens the antagonist muscles. Although 
the physiological effect of the toxin seems to be reversible, 
its use helps children learn to control their movements and 
improve function.5,19,20 
We found that the muscle tone of the hip flexors, 
adductors, knee flexors and ankle plantar flexors was 
significantly reduced at the three-month assessment. 
However, this effect on spasticity did not last until the end 
of the sixth months because muscle tone increased between 
Table 3 - Tardieu scores.
MUSCLES Initial
Mean ±SD
Third month
Mean ±SD
Sixth month
Mean ±SD
Hip Adductor Muscles
                    Right
                    Left
1.36 ±1.14
1.39 ±1.13
1.30 ±1.16
1.35 ±1.16
1.32 ±1.06
1.38 ±1.04
Hamstring Muscles
                    Right
                    Left
1.56 ±1.05
1.60 ±1.03
1.45 ±1.10
1.50 ±1.08
1.57 ±0.93
1.57 ±0.93
Gastrosoleus Muscles
                    Right
                    Left
2.18 ±1.11 ¥
2.18 ±1.20 ¥
1.95 ±1.00
 2.02 ±1.15 †
2.04 ±1.02
2.16 ±1.10
¥ Initial and third month comparisons were statistically different (p<0.05). †Third and sixth month comparisons were statistically different (p<0.05).
Table 4 - Scores of the Five Dimensions of GMFM–88. 
GMFM Initial
Mean ±SD
Third month
Mean ±SD
Sixth month
Mean ±SD
Total 162.35 ±65.48 *¶ 169.85 ±63.61 † 171.47 ±61.86
Lying and Rolling  25.09 ±3.17 § 25.74 ±2.56 25.87 ±2.46
Crawling and Kneeling                      22.59 ±3.40 §¥ 23.08 ±2.96 23.16 ±2.93
Sitting 47.90 ±17.18 ¥¶ 49.19 ±16.52 49.87 ±15.70
Standing 15.00 ±13.50 *¶ 16.64 ±13.71 17.00 ±13.91
Walking, Running, Jumping       20.30 ±17.79 *¶ 21.77 ±18.08 22.45 ±18.35
GMFM: Gross motor function measurement scale. BTX-A: Botulinum toxin type A. *Initial and third month comparisons were statistically different 
(p<0.001). ¥Initial and third month comparisons were statistically different (p<0.05). ¶Initial and sixth month comparisons were statistically different 
(p<0.001). §Initial and sixth month comparisons were statistically different (p<0.05). †Third and sixth month comparisons were statistically different (p<0.05).
Figure 2 - The comparison of initial values of total GMFM–88 with 3rd 
month and 6th month values. † Initial and 3rd month comparisons were 
statistically different (p<0.001). ‡ 3rd and 6th month comparisons were 
statistically different (p<0.05).
Figure 3 - The comparison of the initial scores of GMFM (Walking, Run-
ning, Jumping) dimension with 3rd and 6th month scores. † Initial and 6th 
month comparisons were statistically different (p<0.001).617
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the three- and six-month evaluations. These findings are 
compatible with various recent studies. Scholtes et al.,8 
in their randomized controlled study, demonstrated the 
effectiveness of BTX-A on muscle length, spasticity and 
gait parameters. They observed a reduction in spasticity 
beginning six weeks after multilevel injections and showed 
that the lack of this effect at 24 weeks post-injection 
supported the temporary effect of the toxin due to the 
restoration of neuromuscular junctions. A controlled pilot 
study19 evaluated the effect of BTX-A injection on spastic 
equinus foot in CP patients and showed a significant 
decrease in Ashworth scale scores and an increase in the 
range of motion of the ankle joint at the end of the first 
month, which was supported by both pedobarometry and 
surface EMG findings.21 
Despite the temporary effect of BTX-A, the effect on 
motor functions could last for a longer period of time. In 
our study, we determined an increase in the total GMFM-
88 score and various dimension scores (lying and rolling, 
crawling and kneeling, sitting, standing, walking-running-
jumping) at the three-month evaluation, an effect that did 
not disappear at the six-month evaluation. Despite these 
findings, there was no significant difference in GMFCS 
I-V. We believe that the change in motor abilities is better 
reflected by the GMFM-88 score and its five dimensions. 
GMFCS classifies the ordinary performance of the patient, 
not the quality of the present gross motor function. In 
one of our previous studies involving 18 CP patients, we 
demonstrated reduced spasticity, increased range of motion 
and improved GMFM–88 scores five weeks after multilevel 
BTX injections. Although the range of motion and spasticity 
findings were similar to their initial values at the 12th week 
post-injection, the improvements in GMFM–88 scores 
were still significant. However, in that study, we did not 
use the GMFCS for the classification of ambulatory status 
of the patients.9 Ross et al.22 evaluated the relationship 
between spasticity, strength and functional measures in a 
retrospective study and found that the GMFM scores did 
not correlate with spasticity. Their results showed little or 
no significant relationship between spasticity and function. 
This finding might help to explain our observation at the 
six-month post-injection assessment, as the patients seemed 
to be functionally better despite the fact that their spasticity 
had almost returned to baseline levels. Bjornson et al.,2 in 
their randomized placebo-controlled study, documented 
functional improvement by means of increased GMFM–66 
and GMFM–88 scores at the sixth month post-injection. 
They explained this finding as reflecting the adjustment 
to the changes in motor strength, range of motion and 
spasticity. This finding was supported by a study by Scholtes 
et al.,23 which reported improvements in GMFM–66 scores 
at the sixth month after multilevel injections of CP patients. 
Slawek et al.11 reported that BTX-A reduced spasticity, 
increased the range of motion of the ankle joint and 
increased motor functions in diplegic CP patients who were 
followed for three months post-injection. Although there 
was an increase in spasticity at the end of the third month, 
the GMFM scores did not return to baseline levels. El et 
al.12 treated 14 diplegic CP patients with BTX-A injections 
and then followed them for six months. They observed 
improvements in clinical parameters, such as spasticity 
and motor function, during the first month post-injection. 
Although there was an increase in spasticity at the six-
month evaluation, they also observed an improvement in 
motor function (GMFCS score). In our study, we observed 
significant improvements in GMFM-88 scores but not in 
GMFCS scores at the end of the sixth month. In contrast 
to the study of El et al., which included only diplegic 
CP patients, 26% of the patients in our study group were 
quadriplegic, and 47% were diplegic. Thirty-three percent of 
our patients were GMFCS level IV, and 33% were level V; 
thus, the majority of our study group consisted of severely 
affected patients. This methodological difference might 
help to explain our results. However, Weigl et al.7 followed 
their patients with GMFCS and used a goal attainment 
scale (GAS). They found no significant improvements in 
GMFCS scores and concluded that BTX-A treatment did not 
maintain improvements in motor functions. They did not use 
GMFM–88 in their study to evaluate gross motor functions, 
and we believe that this evaluation is necessary to make such 
a claim. Nevertheless, their findings are similar to ours. 
Multilevel BTX-A injections for the treatment of 
spasticity in CP, have been widely accepted by many 
researchers for more than 15 years.3 They have been shown 
to achieve better results than single-level treatments in 
children with CP.24 The BTX-A dosage used varied in 
different studies, ranging from 10 U/kg to 25 U/kg for Botox 
and 30 U/kg for Dysport. Willis et al.25 used higher doses 
of Botox (20-25 U/kg) in a controlled study and reported 
them to be safe. They mentioned that both high and low 
doses result in reduced spasticity and an improvement in 
the range of motion. In a recently published study, dose 
of 7.45±2.06 U/ kg Botox, produced improvements in gait 
patterns and increased the range of motion of the ankle in 
patients with spastic diplegic CP.26 In our study, we used 15-
20 U/kg Botox and 30 U/kg Dysport, which can be regarded 
as moderate dosages. 
BTX-A injections should always be used as an adjunctive 
treatment to physiotherapy, occupational therapy and 
orthotic management. It is well-accepted that a combined 
approach of pre- and post-injection physiotherapy provides 
long-term benefits.3,5,17 Stretching of the flexor muscles, 618
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strengthening of the extensor muscles and exercises to 
improve gait should be intensively applied, especially in 
the first weeks, when the toxin is more pharmacologically 
active. Appropriate orthoses should be planned for joint 
stabilization during ambulation and to maintain muscle 
length.8 The patients in our study group received at least six 
months of pre-injection physiotherapy and continued to be 
treated with appropriate conservative treatments consisting 
of intensive physiotherapy (five times/week) for the first 
three weeks and a reduced regimen (three times/week) in 
the following 8 weeks. Although this study is a retrospective 
study without a control group, which is one of its recognized 
limitations, we observed the effectiveness of a conservative 
approach in patients treated with BTX-A. 
In our study, the mean patient age was six years. It is 
believed that better results may be obtained in patients 
who are treated at younger ages. As children grow, the 
risk of fixed contractures and bony deformities increases.3 
Although our study is not an age-matched controlled study, 
we believe that our results support the idea that younger 
children may receive more benefits from multilevel BTX-A 
injections, intensive physiotherapy and appropriate orthotic 
management compared to older children. 
  In conclusion, we believe that optimally timed, 
multilevel BTX-A injections are effective in reducing 
spasticity and maintaining functional gains at six months 
post-injection. We suggest that the evaluation tools for 
this effect should involve more detailed scales, such as 
GMFM–88, to properly demonstrate functional gains. The 
importance of physiotherapy and appropriate orthoses should 
always be mentioned to improve the efficacy of the toxin 
in maintaining improvement in strength, selective motor 
control, balance and gait. 
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